0
Skip to Content
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Folder: ABOUT
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Folder: GET INVOLVED
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Folder: RESEARCH
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Folder: NEED HELP?
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
The Netherlands, International Julia Travagline 12/16/24 The Netherlands, International Julia Travagline 12/16/24

Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET

Dr. Max M. van Noesel, MD. PhD, MSc; – Princess Máxima Center, Utrecht, The Netherlands

Read More
Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma
Northeast, Maryland Julia Travagline 11/20/24 Northeast, Maryland Julia Travagline 11/20/24

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Dr. Rosa Nguyen, M.D., Ph.D. – National Cancer Institute, NIH NCI Pediatric Oncology, Bethesda, MD

Read More
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy

Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy

Dr. Ketan Ghaghada, Ph.D. – Baylor College of Medicine, Houston TX

Read More
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
International, Israel Julia Travagline 11/20/24 International, Israel Julia Travagline 11/20/24

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel

Read More
MYCN-amplified neuroblastoma are addicted to iron and vulnerable to system Xc- inhibition
Northeast, Virginia Julia Travagline 12/8/21 Northeast, Virginia Julia Travagline 12/8/21

MYCN-amplified neuroblastoma are addicted to iron and vulnerable to system Xc- inhibition

MYCN-amplified neuroblastoma are addicted to iron and vulnerable to system Xc- inhibition

Virginia Commonwealth University, Richmond, VA

Read More
Arginine methylation as a potential therapeutic target in high-risk neuroblastoma
New York, Northeast Julia Travagline 8/10/21 New York, Northeast Julia Travagline 8/10/21

Arginine methylation as a potential therapeutic target in high-risk neuroblastoma

Arginine methylation as a potential therapeutic target in high-risk neuroblastoma

University of Rochester, Rochester, NY

Read More
Activation of NF-kB in Neuroblastoma Myeloid Cells
Maryland, Northeast Julia Travagline 8/10/21 Maryland, Northeast Julia Travagline 8/10/21

Activation of NF-kB in Neuroblastoma Myeloid Cells

Activation of NF-kB in Neuroblastoma Myeloid Cells

Johns Hopkins University School of Medicine, Baltimore, MD

Read More
Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression
Georgia, South Julia Travagline 8/10/21 Georgia, South Julia Travagline 8/10/21

Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression

Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression

Emory University – Winship Cancer Institute, Atlanta, GA

Read More
Disrupting Neuroblastoma Tumor-Initiating Cells
New York, Northeast Julia Travagline 8/9/21 New York, Northeast Julia Travagline 8/9/21

Disrupting Neuroblastoma Tumor-Initiating Cells

Disrupting Neuroblastoma Tumor-Initiating Cells

University of Rochester, Rochester, NY

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark